Dr. John Cush RheumNow
3 years 2 months ago
Time to live your life. Do the right thing, make a difference, leave an imprint.. https://t.co/LEY7bFcV2S
Dr. John Cush RheumNow
3 years 2 months ago
Horizon announced its phase II RCT of Daxdilimab (anti-ILT7 mAB targeting dendritic cells) failed to meet its primary endpoint - BICLA response w/ pred ≤7.5 mg/day @wk48 (DAX=PBO). DAX also under study in alopecia areata, DLE, lupus nephritis https://t.co/8zDCWI5vB1 https://t.co/pVIg4ctvC5
Dr. John Cush RheumNow
3 years 2 months ago
Unrecognized Mental Health Problems in Autoimmune Diseases
More than half of patients with auto-immune conditions experience mental health conditions such as depression or anxiety, yet most are rarely asked in clinic about mental health symptoms.
https://t.co/wxuGmuPh7D https://t.co/jMZkH1SIcS
Dr. John Cush RheumNow
3 years 2 months ago
EULAR/ACR Guidance on HLH/MAS
A EULAR/ACR task force has established evidence based, up-to-date guidance, and expert opinion on the evaluation, management and monitoring of patients with HLH and MAS.
https://t.co/rZkxuaCsSf https://t.co/c0kHKmZbyt
Dr. John Cush RheumNow
3 years 2 months ago
Rheumatoid vasculitis (RV) metanalysis: RV decreased sincefrom 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/VADI7DbKSc https://t.co/UwJQmzpmkZ
Dr. John Cush RheumNow
3 years 2 months ago
While COVID rates are near historic lows & far less dangerous, hospitalizations are up 10.3%, ER visits up 7%, pos. tests rose to 6.3% from 5.8% in the last week https://t.co/TFAt4p24au
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week COVID persists, mortality from misdiagnosis, and cervical pain is more than a pain in the neck.
IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published validated classification criteria for symptomatic CPPD disease.
Dr. John Cush RheumNow
3 years 2 months ago
UK-NiCE Guidelines on Gout: Treat to Target to Prevent Irreparable Joint Damage
Indications for Urate-lowering Rx:
- Multiple/troublesome flares
- CKD 3 to 5
- Diuretic Rx
- Tophi
- Chronic gouty arthritis
https://t.co/eUqQpn7QUI https://t.co/eAGTRShYlf
Dr. John Cush RheumNow
3 years 2 months ago
IL-1β inhibitors can be effective in #Gout. Based on metanalysis of 14 studies(10 RCTs), 4367 gout pts (Rx w/ anakinra, canakinumab rilonacept) Shows CAN, RIL better than active comparator at pain; CAN/RIL reduced gout flares https://t.co/57JSFtLLJD https://t.co/RueDE01jHj
Dr. John Cush RheumNow
3 years 2 months ago
Link Between Vitamin D and Psoriasis Severity
More than 8M people in the US experience psoriasis-a person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date.
https://t.co/IMvFS0Vp4v https://t.co/cmQAIQ0U4p
Dr. John Cush RheumNow
3 years 2 months ago
Dr. Joseph Flood (1952-2023) - Past ACR President
Dr Joseph Flood, a past president of the American College of Rheumatology, passed away on July 13, 2023 at age 70 due to complications of liver disease, diabetes and liver cancer.
https://t.co/G0elIbTsGg https://t.co/TaxCBxpOpo
Dr. John Cush RheumNow
3 years 2 months ago
What is your effective treatment for rheumatoid Nodules?
